Daily fosfomycin versus levofloxacin for complicated urinary tract infections.
Publication
, Journal Article
Rouphael, N; Winokur, P; Keefer, MC; Traenkner, J; Drobeniuc, A; Doi, Y; Munsiff, S; Fowler, VG; Evans, S; Oler, RE; Tuyishimire, B; Lee, M ...
Published in: mBio
October 31, 2023
Concerns over resistance and safety have been identified in the current treatment regimen for complicated urinary tract infections. Fosfomycin is a drug that is routinely used for the treatment of uncomplicated cystitis. This study shows that fosfomycin could be an oral alternative as step-down therapy for the treatment of complicated urinary tract infections, with a clinical cure rate comparable to levofloxacin but a lower microbiological success rate 3 weeks from start of antibiotics.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
mBio
DOI
EISSN
2150-7511
Publication Date
October 31, 2023
Volume
14
Issue
5
Start / End Page
e0167723
Location
United States
Related Subject Headings
- Urinary Tract Infections
- Levofloxacin
- Humans
- Fosfomycin
- Cystitis
- Anti-Bacterial Agents
- 3207 Medical microbiology
- 3107 Microbiology
- 3101 Biochemistry and cell biology
- 0605 Microbiology
Citation
APA
Chicago
ICMJE
MLA
NLM
Rouphael, N., Winokur, P., Keefer, M. C., Traenkner, J., Drobeniuc, A., Doi, Y., … DMID 15-0045 study group. (2023). Daily fosfomycin versus levofloxacin for complicated urinary tract infections. MBio, 14(5), e0167723. https://doi.org/10.1128/mbio.01677-23
Rouphael, Nadine, Patricia Winokur, Michael C. Keefer, Jessica Traenkner, Ana Drobeniuc, Yohei Doi, Sonal Munsiff, et al. “Daily fosfomycin versus levofloxacin for complicated urinary tract infections.” MBio 14, no. 5 (October 31, 2023): e0167723. https://doi.org/10.1128/mbio.01677-23.
Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, et al. Daily fosfomycin versus levofloxacin for complicated urinary tract infections. mBio. 2023 Oct 31;14(5):e0167723.
Rouphael, Nadine, et al. “Daily fosfomycin versus levofloxacin for complicated urinary tract infections.” MBio, vol. 14, no. 5, Oct. 2023, p. e0167723. Pubmed, doi:10.1128/mbio.01677-23.
Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, Munsiff S, Fowler VG, Evans S, Oler RE, Tuyishimire B, Lee M, Ghazaryan V, Chambers HF, DMID 15-0045 study group. Daily fosfomycin versus levofloxacin for complicated urinary tract infections. mBio. 2023 Oct 31;14(5):e0167723.
Published In
mBio
DOI
EISSN
2150-7511
Publication Date
October 31, 2023
Volume
14
Issue
5
Start / End Page
e0167723
Location
United States
Related Subject Headings
- Urinary Tract Infections
- Levofloxacin
- Humans
- Fosfomycin
- Cystitis
- Anti-Bacterial Agents
- 3207 Medical microbiology
- 3107 Microbiology
- 3101 Biochemistry and cell biology
- 0605 Microbiology